CA2303401A1 - Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment - Google Patents

Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment Download PDF

Info

Publication number
CA2303401A1
CA2303401A1 CA002303401A CA2303401A CA2303401A1 CA 2303401 A1 CA2303401 A1 CA 2303401A1 CA 002303401 A CA002303401 A CA 002303401A CA 2303401 A CA2303401 A CA 2303401A CA 2303401 A1 CA2303401 A1 CA 2303401A1
Authority
CA
Canada
Prior art keywords
ser
seq
pro
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002303401A
Other languages
English (en)
French (fr)
Inventor
Mark A. Bolanowski
Maire H. Caparon
Gerald F. Casperson
Susan A. Gregory
Barbara K. Klein
John P. Mckearn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2303401A1 publication Critical patent/CA2303401A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
CA002303401A 1997-10-01 1998-09-30 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment Abandoned CA2303401A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6060997P 1997-10-01 1997-10-01
US60/060,609 1997-10-01
PCT/US1998/020464 WO1999016889A1 (en) 1997-10-01 1998-09-30 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment

Publications (1)

Publication Number Publication Date
CA2303401A1 true CA2303401A1 (en) 1999-04-08

Family

ID=22030604

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303401A Abandoned CA2303401A1 (en) 1997-10-01 1998-09-30 Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment

Country Status (5)

Country Link
EP (2) EP1019515A1 (enExample)
JP (1) JP2001518304A (enExample)
AU (1) AU9673998A (enExample)
CA (1) CA2303401A1 (enExample)
WO (1) WO1999016889A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833794D1 (de) * 1997-12-08 2006-05-04 Beth Israel Hospital Verfahren zur herstellung von anti-angiogene proteine; endostatin, angiostatin oder restin, mit einem expressions-system für hefe pichia
US6797488B1 (en) 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
WO1999061464A1 (en) * 1998-05-28 1999-12-02 Korea Green Cross Corporation Process of purifying angiogenesis inhibitors
US6500431B1 (en) * 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
WO2000054813A2 (en) * 1999-03-15 2000-09-21 Chiron Corporation Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2004240199B2 (en) * 1999-04-30 2007-05-17 Novartis Vaccines And Diagnostics S.R.L. Conserved Neisserial antigens
MXPA02008014A (es) * 2000-02-18 2004-04-05 New York Medical College Composiciones inhibidoras de tumores de 1-nitroacridina.
CA2421251A1 (en) * 2000-09-05 2002-03-14 Karolinska Innovations Ab Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen
US7420036B2 (en) 2000-11-28 2008-09-02 Waisman David M Anti-angiogenic polypeptides
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
EP1501861A4 (en) * 2002-05-06 2007-06-20 Univ Texas TARGETED BINDING PROTEINS FOR THE ADMINISTRATION OF THERAPEUTIC OR DIAGNOSTIC REAGENTS
JP4511108B2 (ja) * 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
WO2004054517A2 (en) 2002-12-13 2004-07-01 Mediomics, Llc Compositions and methods for inhibiting tumor growth and metastasis
WO2008124086A2 (en) * 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2628748A1 (en) 2012-02-14 2013-08-21 Szilak Laboratories Bioinformatics & Molecule-Design Ltd. Angiostatin chimeras and uses thereof
TWI775096B (zh) 2012-05-15 2022-08-21 澳大利亞商艾佛蘭屈澳洲私營有限公司 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
EP2995626B1 (en) * 2013-05-06 2018-07-11 China Pharmaceutical University Bifunctional fusion proteins to inhibit angiogenesis in tumour microenvironment and to activate adaptive immune responses and the genes and uses thereof
CA2942776C (en) 2014-03-17 2023-01-24 Adverum Biotechnologies, Inc. Polyneucleotide cassette and expression vector for expression of a gene in cone cells using truncated m-opsin promoter
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR20170137730A (ko) 2015-03-02 2017-12-13 애드베룸 바이오테크놀로지스, 인코포레이티드 망막 추상체에 폴리뉴클레오타이드의 유리체 내 전달을 위한 조성물 및 방법
GB2545763A (en) 2015-12-23 2017-06-28 Adverum Biotechnologies Inc Mutant viral capsid libraries and related systems and methods
CN114058636A (zh) * 2021-11-16 2022-02-18 大连润生康泰医学检验实验室有限公司 一种转甲状腺素蛋白基因的克隆、表达与纯化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8315980D0 (en) * 1983-06-10 1983-07-13 Biogen Nv Producing hybrid dna sequences
DE3883453T2 (de) * 1987-07-01 1994-03-17 Beecham Group Plc Hybride Plasminogenaktivatoren.
ATE240740T1 (de) * 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
CN1636594B (zh) * 1994-04-26 2012-08-29 儿童医学中心公司 血管生成抑制素和用于抑制血管生成的方法
ATE368051T1 (de) * 1995-04-26 2007-08-15 Childrens Medical Center Angiostatinfragmente und verfahren für deren verwendung
US5824299A (en) * 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
CN1202932A (zh) * 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US5837680A (en) * 1996-02-16 1998-11-17 Children's Medical Center Corporation Pharmaceutical compositions comprising troponin subunits, fragments and analogs thereof and methods of their use to inhibit angiogenesis
HUP0103329A3 (en) * 1998-08-25 2003-09-29 Lexigen Pharmaceuticals Corp L Expression and export of angiostatin and endostatin as immunofusis

Also Published As

Publication number Publication date
EP1705248A1 (en) 2006-09-27
JP2001518304A (ja) 2001-10-16
AU9673998A (en) 1999-04-23
WO1999016889A1 (en) 1999-04-08
EP1019515A1 (en) 2000-07-19

Similar Documents

Publication Publication Date Title
EP1705248A1 (en) Fusion proteins comprising an angiostatin moiety and their use in anti-tumour treatment
CN100422332C (zh) 表达以及分泌制管张素和endostatin的免疫融合物
US6495518B1 (en) Method for importing biologically active molecules into cells
EP0759067B1 (en) Transforming growth factor alpha h1
JP2003530070A (ja) Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出
KR20080082608A (ko) Ｖｅｇｆ 유사체 및 사용 방법
JP2004525074A (ja) 炎症を治療するための方法
US20050063948A1 (en) Methods for targeting interleukin-12 to malignant endothelium
CN100543036C (zh) 递送治疗或诊断试剂的导向蛋白质
EP1070085A1 (en) DUAL A v?b 3? AND METASTASIS-ASSOCIATED RECEPTOR LIGANDS
US7223731B2 (en) Thrombospondin-1 type 1 repeat polypeptides
JPH10262668A (ja) 血管形成誘導因子をコードするタンパク質コード配列を包含するｄｎａ配列
CA2601271A1 (en) Targeted plasminogen activator fusion proteins as thrombolytic agents
CA2338283A1 (en) Multivalent avb3 and metastasis-associated receptor ligands
AU781134B2 (en) Methods for treating tumors using antiangiogenic compounds
AU651330B2 (en) Novel proteins with oncostatin M activity and process for their preparation
US20040052810A1 (en) Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
US20030077818A1 (en) Compositions and methods for targeting interleukin-12 to malignant endothelium

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20080930